TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+5.19%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.8B
AUM Growth
+$2.8B
(+3.6%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
12
Top Buys
| 1 |
Gilead Sciences
GILD
|
$22M |
| 2 |
Thermo Fisher Scientific
TMO
|
$15.1M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$13M |
| 4 |
Johnson & Johnson
JNJ
|
$11M |
| 5 |
Edwards Lifesciences
EW
|
$10.6M |
Top Sells
| 1 |
iShares Biotechnology ETF
IBB
|
$23.6M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$12.8M |
| 3 |
Biogen
BIIB
|
$12.6M |
| 4 |
Amgen
AMGN
|
$12M |
| 5 |
Puma Biotechnology
PBYI
|
$11.6M |
Sector Composition
| 1 | Healthcare | 93.03% |
| 2 | Real Estate | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Gilead Sciences
GILD
$140B
| $227M | 8.11% | 2,801,131 +271,000 | +11% | +$22M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $202M | 7.23% | 1,387,525 -69,080 | -5% | -$10.1M |
|
|
3
Biogen
BIIB
$19.4B
| $153M | 5.48% | 489,604 -40,170 | -8% | -$12.6M |
|
|
4
Amgen
AMGN
$155B
| $116M | 4.13% | 620,274 -64,550 | -9% | -$12M |
|
5
Vertex Pharmaceuticals
VRTX
$100B
| $111M | 3.97% | 731,123 -66,930 | -8% | -$10.2M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $105M | 3.77% | 750,905 | – | – |
|
|
7
Johnson & Johnson
JNJ
$427B
| $104M | 3.71% | 798,932 +84,570 | +12% | +$11M |
|
8
Merck
MRK
$210B
| $94.3M | 3.37% | 1,473,295 | – | – |
|
9
Incyte
INCY
$16.5B
| $80.9M | 2.89% | 693,275 | – | – |
|
10
Regeneron Pharmaceuticals
REGN
$61.5B
| $76.2M | 2.73% | 170,516 -17,150 | -9% | -$7.67M |
|
|
AGN
11
DELISTED
Allergan plc
AGN
| $69.5M | 2.48% | 338,979 +28,369 | +9% | +$5.81M |
|
12
Abbott
ABT
$231B
| $66.7M | 2.39% | 1,250,920 +98,400 | +9% | +$5.25M |
|
13
Illumina
ILMN
$15.8B
| $63.1M | 2.26% | 316,691 +37,731 | +14% | +$7.52M |
|
14
UnitedHealth
UNH
$281B
| $54M | 1.93% | 275,826 -31,650 | -10% | -$6.2M |
|
15
Viatris
VTRS
$12.3B
| $50.3M | 1.8% | 1,603,112 | – | – |
|
16
BioMarin Pharmaceuticals
BMRN
$11.2B
| $46.7M | 1.67% | 501,745 | – | – |
|
17
Medtronic
MDT
$119B
| $45.1M | 1.61% | 580,326 | – | – |
|
|
18
Thermo Fisher Scientific
TMO
$186B
| $41.4M | 1.48% | 219,072 +79,952 | +57% | +$15.1M |
|
19
Jazz Pharmaceuticals
JAZZ
$7.75B
| $40.1M | 1.43% | 273,916 | – | – |
|
|
SHPG
20
DELISTED
Shire pic
SHPG
| $38.6M | 1.38% | 252,113 | – | – |
|
21
Neurocrine Biosciences
NBIX
$13.8B
| $34.5M | 1.23% | 562,467 | – | – |
|
22
Novartis
NVS
$245B
| $34.2M | 1.22% | 398,662 | – | – |
|
23
CVS Health
CVS
$92.8B
| $33.5M | 1.2% | 411,891 | – | – |
|
24
Eli Lilly
LLY
$657B
| $33.2M | 1.19% | 388,100 -105,000 | -21% | -$8.98M |
|
|
25
Teva Pharmaceuticals
TEVA
$21.1B
| $30.9M | 1.11% | 1,756,558 +740,800 | +73% | +$13M |
|